Gary. S. Gillheeney, Sr.
President and Chief Executive Officer
Gary S. Gillheeney, Sr. has served as our President and Chief Executive Officer since 2014. Previously, he served as our Executive Vice President, Chief Operating Officer and Chief Financial Officer from 2003 to 2014 and as our Chief Financial Officer from 2002 to 2003. Prior to joining Organogenesis, Mr. Gillheeney held executive positions at Innovative Clinical Solutions, Ltd., a provider of decision support and clinical knowledge solutions to healthcare staff, from 1999 to 2002, as its Chief Operating Officer, Chief Financial Officer, as well as Treasurer and Secretary. Prior to joining Innovative Clinical Solutions, Mr. Gillheeney held positions as Senior Vice President, Chief Financial Officer, Treasurer, and Assistant Secretary at Providence Energy Corporation. Mr. Gillheeney has a B.S. in Accounting from American International College and an M.B.A. from Bryant College.
Timothy M. Cunningham
Chief Financial Officer
Timothy M. Cunningham has served as our Chief Financial Officer since 2016. Prior to joining Organogenesis, Mr. Cunningham was Chief Financial Officer of Vestigo Ventures, a venture capital firm. Previously, from 2014 to 2015, Mr. Cunningham served as Senior Vice President and Chief Financial Officer of DialogTech. From 2011 to 2014, he was Worldwide Vice President, Finance and Operations, of GFI Software SA. Prior to joining GFI, he was Executive Vice President and Chief Financial Officer of Metatomix from 2001 to 2010 and Senior Vice President and Chief Financial Officer of Mediabridge Technologies from 1997 to 2000. Earlier in his career, Mr. Cunningham was in public accounting with KPMG followed by Pricewaterhouse Coopers. Mr. Cunningham earned a B.S. in Accounting from Boston College and an M.B.A. from Boston University. Mr. Cunningham is a certified public accountant.
Chief Commercial Officer
Brian Grow has served as our Chief Commercial Officer since 2017. Since 2004, he has served in a number of roles at Organogenesis with increasing responsibility, including as our Director of Sales, Commercial Operations, from 2013 to 2016, Associate Director, Marketing, from 2012 to 2013, Project Manager—Apligraf from 2011 to 2013, Regional Sales Manager from 2006 to 2011 and Tissue Regeneration Specialist from 2004 to 2006. Prior to joining Organogenesis, he was a pharmaceutical sales representative for Bristol-Myers Squibb from 2003 to 2004 and a tissue engineering specialist for Innovex/Novartis from 2000 to 2003. Mr. Grow earned a B.A. in Psychology from William Jewell College.
Chief Operating Officer
Patrick Bilbo has served as our Chief Operating Officer since 2017. Previously, he served as our Senior Vice President, Regulatory, Government Affairs and Administration and other executive positions from 1999 to 2017. Prior to joining Organogenesis, he was Director, Regulatory and Clinical Affairs, for Cytyc Corporation from 1994 to 1998. Mr. Bilbo earned an M.B.A. from the Boston University Questrom School of Business, an M.A. in Biology and an M.A. in Technology Strategy and Policy from the Boston University Graduate School of Arts & Sciences, and a B.S. degree in Biology from Syracuse University.
Executive Vice President, Strategy and Market Development
Howard Walthall has served as our Executive Vice President, Strategy and Market Development since 2017. Previously, he served as President and CEO of NuTech Medical from 2013 to 2017, as President and CEO of NuTech Spine from 2011 to 2017 and as Vice President and General Counsel of NuTech Medical from 2011 to 2012. Prior to joining NuTech, he was a partner at Burr & Forman LLP from 2006 to 2011 and served as an Adjunct Professor at the University of Alabama School of Law from 2005 to 2011. Mr. Walthall has a B.S.E. in Biomedical and Mechanical Engineering from Duke University and a J.D. from the Cumberland School of Law at Samford University.
Antonio S. Montecalvo
Vice President, Health Policy and Contracting
Antonio S. Montecalvo has served as our Vice President, Health Policy and Contracting since 2017. Since 2003, he has served in various roles at Organogenesis, including as Director of Customer Support Services from 2003 to 2006. Prior to joining Organogenesis, Mr. Montecalvo served as Director of Accounting for Innovative Clinical Solutions, LTD from 2000 to 2003, as Senior Contracts Specialist for UnitedHealth Group from 1996 to 2000 and as a Senior Accountant for Piccerelli, Gilstein & Company, LLP from 1994 to 1996. Mr. Montecalvo holds a B.S. in Accounting from the University of Rhode Island.
Vice President and General Counsel
Lori Freedman has served as our General Counsel since 2017. Prior to joining Organogenesis, Ms. Freedman served as Vice President of Corporate Affairs, General Counsel and Secretary of pSivida Corp., a developer of sustained release drug products, since 2006, and held the same positions at Control Delivery Systems from 2001 to 2006. Prior to that, Ms. Freedman served as Vice President, Business Development, and Counsel of Macromedia, Inc., a provider of software for creating Internet content and business applications, from March 2001 through September 2001. Ms. Freedman also served as Vice President, General Counsel, and Secretary of Allaire Corporation, a provider of Internet infrastructure for building business applications, from 1999 until Allaire’s acquisition by Macromedia in 2001, as Corporate Counsel of Polaroid Corporation from May 1998 to December 1998 and with the law firm of McDermott, Will & Emery.
Zorina Pitkin, PhD, RAC
Senior Vice President, Quality Systems
Zorina Pitkin has served as our Senior Vice President, Quality Systems since 2008. Prior to joining the company, Dr. Pitkin served as Acting Head, Regulatory Affairs at Tolerx, Inc. From 2002 to 2007, she was Senior Vice President, Regulatory and Quality for RenaMed Biologics, Inc., and she also served as Vice President, Regulatory and Quality at Circe Biomedical from 1996 to 2002. Dr. Pitkin’s range of expertise includes the development of Quality System programs and regulatory strategies for cellular therapies, biologic/device combination products, biologics and xenotransplantation. She holds a Ph.D. in Biological Sciences from the Research Institute of Influenza, Russian Academy of Medical Sciences, and is Regulatory Affairs certified. She has served as a member of the USP Tissue and Tissue-based Products Advisory Panel and as a member of the Regulatory Affairs Professional Society Board of Directors.
Shabnam Vaezzadeh, MD, MPA
Vice President, Global Medical & Clinical Affairs
Shabnam Vaezzadeh has served as our Vice President, Global Medical & Clinical Affairs since 2017. Previously, she served as Vice President, Global Medical Affairs at Acelity from 2014 to 2016, as Vice President, Global Medical Affairs for Kinetic Concepts from 2010 to 2014, and as Director, Global Safety for Kinetic Concepts from 2008 to 2009. At Lifescan, Johnson & Johnson, Dr. Vaezzadeh served for 8 years, including as Manager, Product Safety and Surveillance from 2005 to 2007. She has written and lectured extensively on medical affairs, product safety, and medical device development. Dr. Vaezzadeh holds a Doctorate in Medicine from the University of Tehran and an M.P.A. in Health Systems Administration from the University of San Francisco.
Vice President, Manufacturing Operations
Christopher O’Reilly has served as our Vice President, Manufacturing Operations since 2015. Mr. O’Reilly has been with Organogenesis since 1997, starting as a Project Engineer. He has functioned as Director of Process Engineering, East Coast from 2002 to 2015, and as General Manager of West Coast Operations from March 2014 to April 2015. Previously, Mr. O’Reilly served as a Senior Process Engineer for Acambis, Inc., Project Engineer for Genzyme Corporation, Validation Engineer for Kemper-Masterson Inc., and as a Project Engineer for both the Badger Engineers Division of Raytheon, and the Electric Boat Division of General Dynamics. He holds a B.S. in Mechanical Engineering from the University of Massachusetts at Dartmouth.